Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Generic Biologics Bill From Waxman Offers Tax Incentives For Studies On Interchangeability

This article was originally published in The Pink Sheet Daily

Executive Summary

Bill permits comparable products as long as they have no clinically meaningful differences and share the "principal molecular structure features" as innovators.

You may also be interested in...



Generic Biologics Bill’s Key Battleground May Be Senate Health Committee

Reintroduced legislation drops tax credits for development of follow-ons. Sponsors see PDUFA reauthorization as ideal vehicle.

Generic Biologics Bill’s Key Battleground May Be Senate Health Committee

Reintroduced legislation drops tax credits for development of follow-ons. Sponsors see PDUFA reauthorization as ideal vehicle.

CTI Spin-Off Aims To Put Follow-On Biologics In The Clinic Within Two Years

Amgen products eyed as initial candidates, exec tells “The Pink Sheet” DAILY.

Related Content

Topics

UsernamePublicRestriction

Register

PS142970

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel